JOURNAL OF PHILOSOPHICAL INQUIRYBusiness Directories,Company Directories

Company Name: Corporate Name:	JOURNAL OF PHILOSOPHICAL INQUIRY
Company Title:	Beauty Hair Salon in Metarie, La: Salon Sierra - Hair Salon, Beauty Salon, Hair Stylists Metairie New Orleans area * Hair Beauty Salon; hair cuts, hair color, high lights, highlighting, perms, straightening, manicures, pedicures, waxing, formerly Hair Force in Metairie, Louisiana
Company Description:	mike johnson of salon sierra: metairie and new orleans top hair styling studios.
Keywords to Search:	hair salon,metairie, la,beauty salon,hair stylist,beauty salon,hair salon metairie,hair cuts,wedding stylists,metairie,new orleans,hair stylists,waxing,perms,highlights,extensions,hair straightening, toupee, manicures, pedicures, hair salon, beauty salon in old metairie, la.
Company Address:	Box 30,WEST FRANKFORT,IL,USA
ZIP Code: Postal Code:	60614
Telephone Number:	3124401222 (+1-312-440-1222)
Fax Number:	3124400835 (+1-312-440-0835)
Website:	salonsierra. com
Email:
USA SIC Code(Standard Industrial Classification Code):	731304
USA SIC Description:	Media Brokers
Number of Employees:
Sales Amount:
Credit History: Credit Report:
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
GENERAL WATERPROOFING
COMPUCENTER
WHERETOPLAY

Next company profile:
NOSTALGIA PRESS
WORX FROM HOME
THE NET GUYS

Company News:

The New England Journal of Medicine | Research Review Articles on . . .
The New England Journal of Medicine (NEJM) is a weekly general medical journal that publishes new medical research and review articles, and editorial opinion on a wide variety of topics of
Imlunestrant with or without Abemaciclib in Advanced Breast Cancer
Imlunestrant is a next-generation, brain-penetrant, oral selective estrogen-receptor (ER) degrader that delivers continuous ER inhibition, even in cancers with mutations in the gene encoding ERα
Current Issue | New England Journal of Medicine
Explore the current issue of The New England Journal of Medicine (Vol 393 No 21)
Tarlatamab in Small-Cell Lung Cancer after Platinum-Based Chemotherapy
Tarlatamab, a bispecific delta-like ligand 3–directed T-cell engager immunotherapy, received accelerated approval for the treatment of patients with previously treated small-cell lung cancer
Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis
In bronchiectasis, neutrophilic inflammation is associated with an increased risk of exacerbations and disease progression Brensocatib, an oral, reversible inhibitor of dipeptidyl peptidase 1 (DPP
Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis
Methods In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day
Antibiotic Treatment for 7 versus 14 Days in Patients with Bloodstream . . .
Bloodstream infections are associated with substantial morbidity and mortality Early, appropriate antibiotic therapy is important, but the duration of treatment is uncertain In a multicenter, non
Structured Exercise after Adjuvant Chemotherapy for Colon Cancer
Methods In this phase 3, randomized trial conducted at 55 centers, we assigned patients with resected colon cancer who had completed adjuvant chemotherapy to participate in a structured exercise
Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer
Background First-line treatment with encorafenib plus cetuximab (EC) with or without chemotherapy (oxaliplatin, leucovorin, and fluorouracil [mFOLFOX6]) for BRAF V600E–mutated metastatic